Recurrent hotspot mutations affecting IDH1 Arg132 and IDH2 Arg140/Arg172 occur in approximately 20% of AML cases, and whilst their relevance as molecular MRD markers remain to be determined, they are of particular importance due to the availability of targeted inhibitors [22,35,36]. Here, IDH2 is linked to acute myeloid leukemia.